ID.1
Item
locally advanced, inoperable loco-regionally-recurrent, or metastatic breast cancer
boolean
C0278493|C0027627 (UMLS CUI [1,1])
C0205187 (UMLS CUI [1,2])
ID.2
Item
estrogen and/or progesterone positive disease
boolean
C0019929 (UMLS CUI [1])
ID.3
Item
progression of disease after antiestrogen therapy
boolean
C0242656 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
ID.4
Item
measurable disease
boolean
C0012634 (UMLS CUI [1])
ID.5
Item
postmenopausal
boolean
C0232970 (UMLS CUI [1])
ID.6
Item
eastern cooperative oncology group (ecog) performance status 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
ID.7
Item
previous endocrine therapy, other than antiestrogen therapy
boolean
C0205394 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
ID.8
Item
more than 1 prior chemotherapy regimen
boolean
C0392920 (UMLS CUI [1])
ID.9
Item
previous therapy with farnesyl transferase inhibitor
boolean
C1517132 (UMLS CUI [1])
ID.10
Item
presence of rapidly progressive, life-threatening metastases
boolean
C2826244 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
ID.11
Item
concomitant anticancer treatment
boolean
C0920425 (UMLS CUI [1])
ID.12
Item
other malignancy within the past 5 years
boolean
C0006826 (UMLS CUI [1])
ID.13
Item
symptomatic peripheral neuropathy.
boolean
C0031117 (UMLS CUI [1])